Navigation Links
CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million
Date:7/24/2014

th the action earlier or later than we anticipate, and there is no guarantee that we will ultimately prevail; if we do not prevail in such action, or if C.R. Bard obtains an injunction, we may be prohibited from selling any version of PerClot in the U.S., or we may have to pay substantial royalties or damages when we sell PerClot in the U.S.; our ability to fully realize our investment in our agreements with Starch Medical, Inc. is dependent on our ability to sell PerClot in the U.S. at a reasonable rate of return, which may be materially negatively impacted by any royalty that we might be required to pay; we will not fully realize the potential benefits of our ProCol distribution agreement with Hancock Jaffe Laboratories, Inc. if Hancock Jaffe fails to obtain FDA approval of its PMA Supplement associated with its new manufacturing facilities; Hancock Jaffe may experience delays and/or difficulties in obtaining the FDA approval, or events could transpire that prevent Hancock Jaffe from making the manufacturing facilities operational at all; we may experience currently unforeseen difficulties related to our ability to successfully market and distribute ProCol; our beliefs regarding the market opportunity for ProCol may be incorrect, and even if correct, there is no guarantee that we will successfully grow ProCol sales or fully realize the potential benefits of any clinical advantages of the product; our controlled European launch of, and increased sales efforts in the U.S. with respect to, the HeRO device may not be successful; integration efforts with respect to newly acquired products may be more costly and take longer than expected; we may receive impaired materials or supplies that do not meet our standards; the recall of materials or supplies by our vendors or suppliers or our inability to obtain materials and supplies could have a material, adverse effect on our business; we continue to evaluate expansion through acquisitions, licenses, investment
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
4. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Initiation of Quarterly Cash Dividend
7. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. CryoLife Receives Expanded Indication for BioFoam in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
11. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data standards ... been published for use on the CDISC website . These three Therapeutic ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing ... as a simple way to get the natural ingredients that may help with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be disclosing ... discussed in a June 8, 2015 article published by Nasdaq , the powerful ... caused by its computer-driven cars, which such industry players as Tesla CEO Elon Musk ...
(Date:7/30/2015)... CA (PRWEB) , ... July ... ... recently released a video, “Beachside Nursing Center,” to announce its position as ... five-star ratings. Beachside's administrator and staff members support the CMS rating system, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a New Way ... Training Capability , World renown body weight trainer, Paul Ziachik, announces today ... dramatically increases a person’s training capability. , The American College of Sports Medicine ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... , CHICAGO, Nov. 24 The holiday season can be ... But for many people, especially those recovering from an eating ... failures and anxiety about an uncertain future. Family gatherings with ... be challenging and sometimes awkward. , "In my ...
... , , FLINT, Mich., Nov. 24 ... insurance plans designed specifically for individuals 18 to 64 ... coverage directly. , The new HealthPlus Signature ... agents and brokers throughout the HealthPlus service area. More information, ...
... ... but research will be presented at the upcoming 2009 Advances in Inflammatory Bowel Diseases, ... that may identify a causative mutation for Crohn’s disease. , ... New York, NY (Vocus) November 24, 2009 ...
... , PITTSBURGH, Nov. 24 While the ... this time of the year can be difficult for those ... every day is difficult for children and families. The holiday ... , The Highmark Caring Place, A Center for Grieving Children, ...
... Ala., Nov. 24 HealthSouth Corporation (NYSE: HLS ) ... Lynch 2009 Credit Conference in New York on Dec. 2-3, 2009. ... be speaking on Thursday, Dec. 3, 2009, at 3:40 p.m. ET. ... http://investor.healthsouth.com by clicking on an available link. , ...
... rates didn,t differ greatly between high- and low-volume centers, ... Do hospitals that conduct the most angioplasties necessarily produce ... research had suggested that "practice makes perfect" when it ... over 30,000 patients finds low- and high-volume hospitals performing ...
Cached Medicine News:Health News:When Holiday Meals Aren't a Gift 2Health News:When Holiday Meals Aren't a Gift 3Health News:HealthPlus Offers New Insurance Plans for Consumers Seeking Health Coverage on Their Own 2Health News:HealthPlus Offers New Insurance Plans for Consumers Seeking Health Coverage on Their Own 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:Highmark Caring Place Resources Help Children and Families Who Are Grieving During the Holidays 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3
Extended angled sharp electrode - 1/box....
... 200, the state of the art in ... Zeiss optics with,the wide range of ICS ... as well as with an unusual scope ... stability and unique ergonomically designed. And Axiovert ...
... the way it implements the confocal principle, ... system is unmatched. It allows multi fluorescence ... and efficiency. Unprecedented flexibility for individual applications. ... guarantee fast and efficient structural and functional ...
... are the hallmark of these stereozoom fluorescent ... The top (incident) circular 9W fluorescent ring ... remaining cool to the touch. Binocular and ... to 44x zoom magnification or high-power 20x ...
Medicine Products: